Abstract
Therapy of hepatitis with standart combination of pegylated interferon and ribavirin is of limited efficacy (approx. 50% cured patients). New development has been reached by implementation of new inhibitors of viral proteases into combination therapy.
This article describes complete medical profile of new direct acting antiviral agent telaprevir (viral protease inhibitor)